Abstract
Chitosan (CHI) has antimicrobial and anticancer characteristics in addition to being biodegradable and biocompatible as a polymer. It has recently attracted a lot of attention as a potential drug carrier framework material for pulmonary therapeutic transport, particularly in the context of treating infectious diseases and cancer. CHI mucoadhesive, permeation-enhancing, and site- and cell-specific properties all play a key role in the therapeutic carrier's efficacy in the pulmonary circulation. Numerous microencapsulation and micro-nanomixing techniques have been developed to provide nanocarriers with the proper aerodynamic profile for effective pulmonary aerosolization and inhalation. Acute respiratory distress syndrome (ARDS) and cancer are the outcomes of a subsequent infection with COVID-19. The effectiveness of anti-CoV and anticancer treatments using CHI and its derivatives varies with molecular weight, substituent type, and degree of substitution. From the viewpoint of drug delivery (DD), in addition to its therapeutic performance, CHI is anticipated to attract more attention throughout the coming decade.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
